1015 Participants Needed

AZD0486 + Rituximab for Follicular Lymphoma

Recruiting at 53 trial locations
AC
Overseen ByAstraZeneca Clinical Study Information Center
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: AstraZeneca
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What evidence supports the effectiveness of the drug combination AZD0486 and Rituximab for treating follicular lymphoma?

Rituximab, when combined with chemotherapy, has been shown to improve response rates and progression-free survival in patients with follicular lymphoma, and it is considered a standard treatment. Although specific data on AZD0486 is not provided, the combination of rituximab with other biological agents has been effective in enhancing treatment outcomes.12345

What safety data exists for AZD0486 + Rituximab treatment?

Rituximab, used in various conditions, generally has tolerable side effects like fevers and chills during the first infusion, but can also cause rare cases of severe thrombocytopenia (low platelet count). It is considered safe for long-term use in some lymphomas, though some patients may experience reversible low blood cell counts.678910

What makes the drug AZD0486 + Rituximab unique for treating follicular lymphoma?

The combination of AZD0486, a novel bispecific antibody targeting CD19 and CD3, with Rituximab, a well-established monoclonal antibody targeting CD20, offers a unique approach by engaging both T-cells and B-cells to enhance the immune response against follicular lymphoma, potentially improving treatment outcomes compared to standard therapies that typically target only one type of cell.67111213

What is the purpose of this trial?

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the AZD0486 plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Research Team

CC

Chan Cheah

Principal Investigator

Sir Charles Gairdner Hospital (SCGH)

Eligibility Criteria

This trial is for patients with untreated Follicular Lymphoma. Participants must meet certain health criteria to join, but specific inclusion and exclusion details are not provided here.

Inclusion Criteria

My liver, blood, kidney, and heart are functioning well.
My lymphoma is classified as FL Grade 1-3A.
I need treatment for my condition as per GELF guidelines.
See 3 more

Exclusion Criteria

I cannot receive BR, RCVP, or R-CHOP treatments due to health reasons.
Presence of >5000 circulating lymphoma cells
My lymphoma is either Grade 3B or suspected to be transforming into a more aggressive form.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Safety Run-in

This part will compare dose levels of AZD0486 in combination with rituximab to establish the RP3D

Up to 1 year

Phase III Treatment

Participants receive AZD0486 plus rituximab or Investigator's choice of standard chemoimmunotherapy regimen

Up to 10 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 10 years

Treatment Details

Interventions

  • AZD0486
  • Rituximab
Trial Overview The study tests the effectiveness and safety of a new combination: AZD0486 plus rituximab against standard immunochemotherapy regimens (R-CHOP, R-CVP, BR) in untreated Follicular Lymphoma patients.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Rituximab, AZD0486 - BExperimental Treatment1 Intervention
AZD0486 regimen B plus rituximab
Group II: Rituximab, AZD0486 - AExperimental Treatment1 Intervention
AZD0486 regimen A plus rituximab
Group III: ChemoimmunotherapyActive Control3 Interventions
Investigator's choice between 3 standard immunochemotherapy regimen (R-CHOP or R-CVP followed by rituximab maintenance, or B-R)

Find a Clinic Near You

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from ร‰cole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from ร‰cole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Findings from Research

Rituximab is highly effective for treating low-grade CD20+ lymphoma, especially when combined with chemotherapy, which is the standard treatment for follicular lymphoma (FL).
The efficacy of rituximab can be enhanced by combining it with biological agents like interferon-alpha-2a, bortezomib, or lenalidomide, but more research is needed to determine the best combinations and timing of these treatments.
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.Kimby, E.[2021]
In a study of 60 patients with symptomatic or bulky follicular lymphoma, a combination of short-course chemoimmunotherapy (CHOP-R) followed by radioimmunotherapy (RIT) led to a significant increase in complete response (CR) rates, from 40% after CHOP-R to 82% after RIT, as assessed by imaging.
The study found that patients who did not achieve a complete metabolic response on PET imaging after CHOP-R had a higher risk of relapse, highlighting the importance of early PET assessment in predicting treatment outcomes.
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.Jacobs, SA., Swerdlow, SH., Kant, J., et al.[2016]
Rituximab-treated patients with B cell non-Hodgkin lymphoma (NHL) showed significant humoral immunodeficiency, with only 20% responding to diphtheria and pneumococcal vaccinations, despite having relatively normal IgG levels.
Subcutaneous immunoglobulin (subq Ig) therapy was well-tolerated and significantly increased serum IgG levels, leading to a reduction in nonneutropenic infections, indicating its efficacy as a supportive treatment for these patients.
The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab.Mustafa, SS., Jamshed, S., Vadamalai, K., et al.[2021]

References

Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma. [2021]
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. [2016]
The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab. [2021]
Use of rituximab in patients with follicular lymphoma. [2019]
Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. [2017]
Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. [2018]
Use of rituximab, the new FDA-approved antibody. [2019]
Rescue Therapy Using Rituximab for Multiple Sclerosis. [2017]
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. [2021]
Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma. [2023]
Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. [2015]
Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck. [2015]
INFECTIOUS COMPLICATIONS AS A PREDICTOR OF MORTALITY IN PATIENTS WITH NON-HODGKIN LYMPHOMA RECEIVING RITUXIMAB-CONTAINING CHEMOTHERAPY. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity